Insight Molecular Diagnostics Inc. (IMDX) vs Immunic, Inc. (IMUX)
A side-by-side comparison of Insight Molecular Diagnostics Inc. and Immunic, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMDX
Insight Molecular Diagnostics Inc.
$3.42HealthcareDelayed quote: Oct 6, 2026, 3:30 PM EDT
IMUX
Immunic, Inc.
$7.81HealthcareDelayed quote: Oct 6, 2026, 3:30 PM EDT
Total return — IMDX vs IMUX
growth of $100 · dividends reinvested · last 10yIMDX -96.9% (-29.4%/yr)IMUX -99.7% (-43.5%/yr)IMDX compounded faster over this window
Log scale — wide-divergence pair
IMDX IMUX
IMDX vs IMUX: by the numbers
- •IMDX is the larger company ($110M vs $106M market cap).
- •Both run net losses; IMUX's is the smaller (0.00% vs -2955.63% net margin).
Metrics side by side
Valuation
| Metric | IMDX | IMUX |
|---|---|---|
| P/S ratio | 66.03 | N/A |
| P/B ratio | N/A | 0.83 |
Profitability
| Metric | IMDX | IMUX |
|---|---|---|
| Gross margin | 11.17% | 0.00% |
| Operating margin | -754.08% | 0.00% |
| Net margin | -2955.63% | 0.00% |
| ROE | N/A | -87.45% |
| ROIC | -223.06% | -92.16% |
Growth (annualized)
| Metric | IMDX | IMUX |
|---|---|---|
| Revenue CAGR (5Y) | 27.24% | N/A |
| Total return CAGR (5Y) | -44.39% | -35.70% |
Frequently asked
- How have IMDX and IMUX total returns compared?
- Over the past 10 years, IMDX delivered -29.11% and IMUX delivered -43.80% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Insight Molecular Diagnostics ROEImmunic ROEInsight Molecular Diagnostics operating marginImmunic operating marginInsight Molecular Diagnostics revenue growthImmunic revenue growthInsight Molecular Diagnostics free cash flowImmunic free cash flow
Insight Molecular Diagnostics & Immunic appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.